Cambridge Investment Research Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $934K | Buy |
3,877
+1,919
| +98% | +$420K | ﹤0.01% | 2378 |
|
|
2026
Q1 | $370K | Buy |
1,958
+532
| +37% | +$93K | ﹤0.01% | 3084 |
|
|
2025
Q4 | $242K | Sell |
1,426
-157
| -10% | -$24.1K | ﹤0.01% | 3402 |
|
|
2025
Q3 | $209K | Buy |
+1,583
| New | +$190K | ﹤0.01% | 3450 |
|
|
2025
Q2 | – | Sell |
-7,504
| Closed | -$932K | – | 3695 |
|
|
2025
Q1 | $932K | Buy |
7,504
+2,067
| +38% | +$270K | ﹤0.01% | 1924 |
|
|
2024
Q4 | $670K | Sell |
5,437
-778
| -13% | -$91.7K | ﹤0.01% | 2190 |
|
|
2024
Q3 | $692K | Buy |
6,215
+189
| +3% | +$20.7K | ﹤0.01% | 2147 |
|
|
2024
Q2 | $643K | Buy |
+6,026
| New | +$663K | ﹤0.01% | 2094 |
|
|
2023
Q4 | – | Sell |
-1,941
| Closed | -$251K | – | 3250 |
|
|
2023
Q3 | $251K | Sell |
1,941
-457
| -19% | -$60.9K | ﹤0.01% | 2636 |
|
|
2023
Q2 | $297K | Buy |
2,398
+96
| +4% | +$12.9K | ﹤0.01% | 2529 |
|
|
2023
Q1 | $337K | Sell |
2,302
-2,480
| -52% | -$367K | ﹤0.01% | 2388 |
|
|
2022
Q4 | $762K | Buy |
4,782
+1,088
| +29% | +$159K | ﹤0.01% | 1701 |
|
|
2022
Q3 | $492K | Buy |
3,694
+34
| +0.9% | +$5.17K | ﹤0.01% | 1947 |
|
|
2022
Q2 | $571K | Sell |
3,660
-84
| -2% | -$12.9K | ﹤0.01% | 1866 |
|
|
2022
Q1 | $583K | Sell |
3,744
-1,226
| -25% | -$178K | ﹤0.01% | 1982 |
|
|
2021
Q4 | $633K | Sell |
4,970
-987
| -17% | -$130K | ﹤0.01% | 1925 |
|
|
2021
Q3 | $776K | Buy |
5,957
+121
| +2% | +$18.3K | ﹤0.01% | 1730 |
|
|
2021
Q2 | $1.04M | Buy |
5,836
+2,587
| +80% | +$448K | 0.01% | 1508 |
|
|
2021
Q1 | $534K | Sell |
3,249
-1,734
| -35% | -$285K | ﹤0.01% | 1857 |
|
|
2020
Q4 | $822K | Buy |
4,983
+1,790
| +56% | +$267K | ﹤0.01% | 1433 |
|
|
2020
Q3 | $455K | Buy |
+3,193
| New | +$396K | ﹤0.01% | 1661 |
|
|
2019
Q3 | – | Sell |
-2,979
| Closed | -$425K | – | 2378 |
|
|
2019
Q2 | $425K | Buy |
+2,979
| New | +$400K | ﹤0.01% | 1539 |
|
|
2018
Q3 | – | Sell |
-1,605
| Closed | -$277K | – | 2271 |
|
|
2018
Q2 | $277K | Buy |
+1,605
| New | +$262K | ﹤0.01% | 1788 |
|
|
2017
Q3 | – | Sell |
-1,462
| Closed | -$227K | – | 2032 |
|
|
2017
Q2 | $227K | Buy |
+1,462
| New | +$224K | ﹤0.01% | 1672 |
|
|
2016
Q1 | – | Sell |
-1,498
| Closed | -$211K | – | 1630 |
|
|
2015
Q4 | $211K | Sell |
1,498
-40
| -3% | -$5.54K | 0.01% | 1335 |
|
|
2015
Q3 | $204K | Sell |
1,538
-630
| -29% | -$108K | 0.01% | 1249 |
|
|
2015
Q2 | $382K | Sell |
2,168
-539
| -20% | -$96.8K | 0.01% | 942 |
|
|
2015
Q1 | $468K | Buy |
2,707
+137
| +5% | +$23.5K | 0.01% | 834 |
|
|
2014
Q4 | $421K | Buy |
2,570
+440
| +21% | +$73K | 0.01% | 864 |
|
|
2014
Q3 | $342K | Sell |
2,130
-420
| -16% | -$64.6K | 0.01% | 1026 |
|
|
2014
Q2 | $375K | Buy |
2,550
+286
| +13% | +$39.7K | 0.01% | 893 |
|
|
2014
Q1 | $314K | Sell |
2,264
-3,642
| -62% | -$548K | 0.01% | 936 |
|
|
2013
Q4 | $747K | Sell |
5,906
-3,069
| -34% | -$318K | 0.03% | 484 |
|
|
2013
Q3 | $825K | Buy |
+8,975
| New | +$724K | 0.04% | 429 |
|
Other funds holding JAZZ
Cambridge Investment Research Advisors's JAZZ Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 98% in Q2 2026, buying an estimated $420K and bringing the position to 3,877 shares worth $934K. The position accounts for ﹤0.01% of the portfolio, ranked #2378.
Cambridge Investment Research Advisors first reported a position in JAZZ in Q3 2013 and has held it in 34 quarters since. The position peaked at $1.04M in Q2 2021. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Cambridge Investment Research Advisors held 3,877 shares of Jazz Pharmaceuticals worth $934K as of Q2 2026.
- Cambridge Investment Research Advisors bought 1,919 Jazz Pharmaceuticals shares in Q2 2026, an estimated $420K.
- Jazz Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2378 holding.
- Cambridge Investment Research Advisors first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 34 quarters since.
- Cambridge Investment Research Advisors's Jazz Pharmaceuticals position peaked at $1.04M in Q2 2021.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.